Fig. 3: Addition of Myostatin and activin A blockade to semaglutide further improves glucose, HbA1c%, LDL-C and HDL-C. | Nature Communications

Fig. 3: Addition of Myostatin and activin A blockade to semaglutide further improves glucose, HbA1c%, LDL-C and HDL-C.

From: GDF8 and activin A blockade protects against GLP-1–induced muscle loss while enhancing fat loss in obese male mice and non-human primates

Fig. 3: Addition of Myostatin and activin A blockade to semaglutide further improves glucose, HbA1c%, LDL-C and HDL-C.

Male, obese cynomolgus monkeys were treated for 20 weeks with control antibody (white circles, n = 10), Sema (blue squares, n = 9), α-MSTN/α-ActA (orange triangles, n = 8), or Sema + α-MSTN/α-ActA (purple diamonds, n = 10). Clinical chemistry results for a fasting glucose b hemoglobin A1c (HbA1c%), c low-density lipoprotein (LDL-C), and d high-density lipoprotein (HDL-C). Blood for all values was taken in the morning before breakfast. All data points are mean ± SEM. * P < 0.05 vs. vehicle, # P < 0.05 vs. Sema, ^ P < 0.05 vs. α-MSTN + α-ActA, + P < 0.05 vs. baseline for the last timepoint of each group. Stats by two-way RM ANOVA. α-MSTN: anti-myostatin antibody, α-ActA: anti-activin a antibody, sema: semaglutide, DXA dual energy x-ray absorptiometry.

Back to article page